Title | Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer MA |
Secondary Authors | Solomon SD |
Journal | Circulation |
Volume | 132 |
Issue | 5 |
Pagination | 402-14 |
Date Published | 2015 Aug 04 |
ISSN | 1524-4539 |
Keywords | Aged, Aged, 80 and over, Double-Blind Method, Electrocardiography, Female, Follow-Up Studies, Heart Arrest, Heart Failure, Systolic, Hospitalization, Humans, Incidence, Internationality, Male, Middle Aged, Mineralocorticoid Receptor Antagonists, Prognosis, Spironolactone, Stroke Volume, Survival Rate, Treatment Outcome, Ventricular Dysfunction, Left |
Abstract | BACKGROUND: Impairment in left ventricular systolic function has been described in heart failure (HF) with preserved ejection fraction (HFpEF), but its prognostic relevance is not known. We determined whether left ventricular longitudinal strain (LS) is predictive of cardiovascular outcomes in HFpEF beyond clinical and conventional echocardiographic measures. METHODS AND RESULTS: LS was assessed by 2-dimensional speckle-tracking echocardiography at baseline in 447 patients with HFpEF enrolled in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. At a median follow-up of 2.6 years (interquartile range, 1.5-3.9 years), 115 patients experienced the primary composite outcome of cardiovascular death, HF hospitalization, or aborted cardiac arrest. Impaired LS, defined as an absolute LS CONCLUSIONS: Impaired left ventricular systolic function is a powerful predictor of HF hospitalization, cardiovascular death, or aborted cardiac arrest in HFpEF independent of clinical predictors. Impaired LS represents a novel imaging biomarker to identify patients with HFpEF at particularly high risk for cardiovascular morbidity and mortality. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302. |
DOI | 10.1161/CIRCULATIONAHA.115.015884 |
Alternate Journal | Circulation |
PubMed ID | 26130119 |
PubMed Central ID | PMC4526442 |
Grant List | HHSN268201100012C / HL / NHLBI NIH HHS / United States K08 HL116792 / HL / NHLBI NIH HHS / United States HHSN268201100009I / HL / NHLBI NIH HHS / United States HHSN268200425207C / HC / NHLBI NIH HHS / United States HHSN268201100010C / HL / NHLBI NIH HHS / United States HHSN268201100008C / HL / NHLBI NIH HHS / United States HHSN268201100005G / HL / NHLBI NIH HHS / United States HHSN268201100008I / HL / NHLBI NIH HHS / United States HHSN268201100007C / HL / NHLBI NIH HHS / United States HHSN268201100011I / HL / NHLBI NIH HHS / United States HHSN268201100011C / HL / NHLBI NIH HHS / United States HHSN268201100006C / HL / NHLBI NIH HHS / United States HHSN268201100005I / HL / NHLBI NIH HHS / United States HHSN268201100009C / HL / NHLBI NIH HHS / United States HHSN268201100005C / HL / NHLBI NIH HHS / United States HHSN268201100007I / HL / NHLBI NIH HHS / United States |